|
rs13181
|
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
The ERCC1 rs13181 and XPD rs11615 polymorphisms were not predictive of clinical outcome for HCC patients receiving TACE (both p > 0.05).
|
26918371 |
2016 |
|
rs13181
|
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
The genotypes of XPD Asp312Asn (p=0.2493), Lys751Gln (p=0.7547) and promoter -114 (p=0.8702), were not associated with susceptibility for colorectal cancer.
|
27069143 |
2016 |
|
rs13181
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Asp312Asn, Lys751Gln and promoter -114 of the XPD gene were not found to be adequate predictive markers for colorectal cancer risk in Taiwan.
|
27069143 |
2016 |
|
rs13181
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conducted a case-control study to investigate the role of ERCC1 rs3212986 and ERCC2 rs13181 gene polymorphisms in the development of breast cancer.
|
26985954 |
2016 |
|
rs13181
|
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
The correlation between ERCC1 polymorphisms (rs11615 and rs3212986) and XPD polymorphisms (rs13181 and rs1799793) with the response rate and overall survival of cancer patients who accept neoadjuvant therapy has been extensively investigated.However, the results are inconclusive.
|
26426637 |
2015 |
|
rs13181
|
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
A significant association was observed between X</span>PD</span> K75</span>1Q polymorphism and the risk of NPC using conditional logistic regression.
|
26086338 |
2015 |
|
rs13181
|
|
Glioma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our meta-analysis strongly suggested that ERCC2 rs13181 was associated with a higher susceptibility to glioma in the Chinese population.
|
26505408 |
2015 |
|
rs13181
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The correlation between ERCC1 polymorphisms (rs11615 and rs3212986) and XPD polymorphisms (rs13181 and rs1799793) with the response rate and overall survival of cancer patients who accept neoadjuvant therapy has been extensively investigated.However, the results are inconclusive.
|
26426637 |
2015 |
|
rs13181
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of this study is to investigate rs13181 ERCC2 (T>G) (Lys751Gln), rs12806698 RRM1 (-269C>A) and rs6759180 (located in the 5'UTR) RRM2 (10126436G>A) gene polymorphisms by using real time PCR technique in patients with NSCLC.
|
26718430 |
2015 |
|
rs13181
|
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results indicated that neither the Asp312Asn nor Lys751Gln XPD polymorphism was related to NHL risk.
|
25962431 |
2015 |
|
rs13181
|
|
Glioma
|
|
0.100 |
GeneticVariation
|
BEFREE |
No significant association was observed between ERCC2 rs13181 polymorphisms and glioma risk.
|
25867436 |
2015 |
|
rs13181
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis indicates that ERCC2 Lys751Gln polymorphism may lead to an increased susceptibility to lung c</span>ancer risk among Caucasians and Asians.
|
24556168 |
2014 |
|
rs13181
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis suggested that the ERCC1 C118T, ERCC2 Asp312Asn, and Lys751Gln may be useful biomarkers to predict the clinical outcomes of the platinum-based chemotherapy in NSCLC patients.
|
24338713 |
2014 |
|
rs13181
|
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our analyses demonstrate that XPD rs13181 may be associated with an increase in the risk of lung cancer among Caucasian populations.
|
24845027 |
2014 |
|
rs13181
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aimed to determine the associations of genetic polymorphisms of excision repair cross-complementation group 1 (ERCC1) rs11615, xeroderma pigmentosum group D (XPD/ERCC2) rs13181, X-ray repair cross complementing group 1 (XRCC1) rs25487, XRCC3 rs1799794, and breast cancer susceptibility gene 1 (BRCA1) rs1799966 from the DNA repair pathway and multiple drug resistance 1 (MDR1/ABCB1) rs1045642 with response to chemotherapy and survival of non-small cell lung cancer (NSCLC) in a Chinese population.
|
24933103 |
2014 |
|
rs13181
|
|
Glioma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, the results of our study suggest that the rs25487, rs25489, rs1799793, and rs13181 SNPs are associated with an increased risk of glioma.
|
24634177 |
2014 |
|
rs13181
|
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
This is the first study on DNA repair genetic polymorphisms in West Algerian population, and it suggests that the XRCC3 Thr241Met and XPD Lys751Gln polymorphisms may not be associated with the CRC risk in this population.
|
24687779 |
2014 |
|
rs13181
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the subgroup analysis by cancer type, XPD Lys751Gln polymorphism had statistically significant association with elevated laryngeal cancer (LC) and nasopharyngeal cancer (NPC) risk under heterozygous comparison and dominant model (P<0.05) and borderline significantly increased risk was found under allele contrast for LC and NPC.
|
24443924 |
2014 |
|
rs13181
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our analyses demonstrate that XPD rs13181 may be associated with an increase in the risk of lung cancer among Caucasian populations.
|
24845027 |
2014 |
|
rs13181
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, Lys751Gln in ERCC2 is associated with lung cancer, and the risk effect probably exists in Caucasians.
|
24368330 |
2014 |
|
rs13181
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our analyses demonstrate that XPD rs13181 may be associated with an increase in the risk of lung cancer among Caucasian populations.
|
24845027 |
2014 |
|
rs13181
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, Lys751Gln in ERCC2 is associated with lung cancer, and the risk effect probably exists in Caucasians.
|
24368330 |
2014 |
|
rs13181
|
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest that the XPD Lys751Gln variant genotype increases the risk of CML.
|
24955348 |
2014 |
|
rs13181
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aimed to determine the associations of genetic polymorphisms of excision repair cross-complementation group 1 (ERCC1) rs11615, xeroderma pigmentosum group D (XPD/ERCC2) rs13181, X-ray repair cross complementing group 1 (XRCC1) rs25487, XRCC3 rs1799794, and breast cancer susceptibility gene 1 (BRCA1) rs1799966 from the DNA repair pathway and multiple drug resistance 1 (MDR1/ABCB1) rs1045642 with response to chemotherapy and survival of non-small cell lung cancer (NSCLC) in a Chinese population.
|
24933103 |
2014 |
|
rs13181
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aimed to determine the associations of genetic polymorphisms of excision repair cross-complementation group 1 (ERCC1) rs11615, xeroderma pigmentosum group D (XPD/ERCC2) rs13181, X-ray repair cross complementing group 1 (XRCC1) rs25487, XRCC3 rs1799794, and breast cancer susceptibility gene 1 (BRCA1) rs1799966 from the DNA repair pathway and multiple drug resistance 1 (MDR1/ABCB1) rs1045642 with response to chemotherapy and survival of non-small cell lung cancer (NSCLC) in a Chinese population.
|
24933103 |
2014 |